Dr. Amy Paller, who has spent 30 years researching the disorder, for the first time has found the reason the disease causes the red skin and has a promising biologic drug to begin testing soon in clinical trials.
In a new study published in the Journal of Allergy and Clinical Immunology, Paller, the Northwestern Medicine chair of dermatology, together with Dr. Emma Guttman-Yassky of Mount Sinai Medical School, discovered that an arm of the immune system – the Th17 pathway – in these patients is way too active, and the higher its activity, the worse the disease severity.
Paller is about to launch a clinical trial to test a new biologic (a cutting-edge drug) for it, with the goal of targeting and calming down this pathway.
More information is available on Northwestern University website.
NIBIB researchers have created a nanovaccine that could make a current approach to cancer immunotherapy more effective while also reducing side effects. The nanovaccine helps to efficiently deliver a unique DNA sequence to immune cells – a sequence derived from bacterial DNA and used to trigger an immune reaction. The nanovaccine also protects the DNA from being destroyed inside the body, where DNA-cutting enzymes are pervasive, as well as outside of the body when exposed to warm temperatures while being stored or transported. The researchers successfully tested the nanovaccine in mice and detailed their work in the March 2016 issue of the journal Nanoscale.
Tumors evade the immune system by suppressing its ability to recognize and kill cancer cells. The goal of immunotherapy is to normalize and harness the body’s immune system so that it can more effectively fight the Tumors.
Full story is available from NIBIB Website.